More Exciting Days Ahead - Boring 4 Months Almost OverFor those expecting some guidance on the latest financials, don't hold your breath until post split. Both companies are posed to come out of the gate running post split ..... - expect Viemed to show strong guidance with strong growth history and guidance (30% plus range). Should see a multiple expansion on valuation based on this information alone. Outstanding shares will be only 37 million so we won't see the penny traders moving this stock much. I also expect institutional interest to increase with a stock price much above $2 - $4 (post split and consolidation) - New PHM will only increase in value once Crawford follows through on his acquisition strategy. I am expecting at least 2 acquisitions in early 2018 as he has been teeing these strategic moves during 2017 and they should be close to simply "dotting the i's and crossing the t's). Crawford has demonstrated strong management execution on capturing synergies (lowering costs) with the prior acquisitions and we should expect he will execute successfully with a number of acquisitions over the next few years. As the acquisitions and new financials are announces, we can expect the "New PHM" valuation to increase as it should also experience a multiple expansion. Looking forward to 2018!!! It's been a slow and boring 4 months during this transition phase.